Phase 1 Program of ALZ-801, a Novel Prodrug of Tramiprosate with Improved Tolerability, Supports Bridging to Upcoming Phase 3 Program
Presented at the 9th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, held in San Diego, California Introduction ALZ-801 is a novel, orally bioavailable, small molecule prodrug of tramiprosate with substantially improved pharmaceutical properties. Tramiprosate, the active moiety released after administration of ALZ-801, is a β-amyloid (Aβ) anti-aggregation agent that inhibits the formation of Aβ oligomers